Stabilization of disease after targeted therapy in a Thymic carcinoma with kit mutation detected by clinical next-generation sequencing

Journal of Thoracic Oncology

Volumn 9, Issue 2, 2014, Pages

  Hagemann, Ian S ^a   Govindan, Ramaswamy ^b   Javidan Nejad, Cylen ^c   Pfeifer, John D ^a   Cottrell, Catherine E ^a  

^a Department of Pathology and Immunology   (United States)

^b Section of Medical Oncology   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GEMCITABINE; IMATINIB; PACLITAXEL; PEMETREXED;

ADULT; ARTICLE; CASE REPORT; DISEASE COURSE; DRUG EFFECT; DRUG TARGETING; DRUG WITHDRAWAL; FEMALE; GENE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; KIT GENE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THYMUS CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED, 80 AND OVER; BENZAMIDES; CARCINOMA, SQUAMOUS CELL; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; REMISSION INDUCTION; THYMUS NEOPLASMS;

EID: 84893360841     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182a7d22e     Document Type: Article

References (26)

1. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
2. Quintás-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008;5:737-740.
3. Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004;279:31655-31663.
4. Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G. Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 2011;29:4820-4827.
5. Hammond-Thelin LA, Thomas CR Jr. Systemic therapeutic options in thymic malignancies: a glimmer of hope. Rev Recent Clin Trials 2007;2:191-205.
6. Girard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009;15:6790-6799.
7. Lamarca A, Moreno V, Feliu J. Thymoma and thymic carcinoma in the target therapies era. Cancer Treat Rev 2013;39:413-420.
8. Postow MA, Robson ME. Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications. Clin Sarcoma Res 2012;2:16.
9. Caram MV, Schuetze SM. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options. J Surg Oncol 2011;104:888-895.
10. Schirosi L, Nannini N, Nicoli D, et al. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann Oncol 2012;23:2409-2414.
11. Debiec-Rychter M, Dumez H, Judson I, et al; EORTC Soft Tissue and Bone Sarcoma Group. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-695.
12. Kleinbaum EP, Lazar AJ, Tamborini E, et al. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. Int J Cancer 2008;122:711-718.
13. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349.
14. Di?el U, Oztuzcu S, Be?en AA, et al. Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer 2011;71:109-112.
15. Nakagawa K, Matsuno Y, Kunitoh H, Maeshima A, Asamura H, Tsuchiya R. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 2005;128:140-144.
16. Salter JT, Lewis D, Yiannoutsos C, et al. Imatinib for the treatment of thymic carcinoma. J Clin Oncol 2008;26:8116.
17. Girard N. Thymic tumors: relevant molecular data in the clinic. J Thorac Oncol 2010;5(10 Suppl 4):S291-S295.
18. Tarn C, Merkel E, Canutescu AA, et al. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res 2005;11:3668-3677.
19. Buti S, Donini M, Sergio P, et al. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. J Clin Oncol 2011;29:e803-e805.
20. Rossi V, Donini M, Sergio P, Passalacqua R, Rossi G, Buti S. When a thymic carcinoma "becomes" a GIST. Lung Cancer 2013;80:106-108.
21. Ströbel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004;350:2625-2626.
22. Yoh K, Nishiwaki Y, Ishii G, et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008;62:316-320.
23. Bisagni G, Rossi G, Cavazza A, et al. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thoracic Oncol 2009;4:773-775.
24. Robinson JT, Thorvaldsdóttir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol 2011;29:24-26.
25. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997;18:2714-2723.
26. Giaccone G, Rajan A, Ruijter R, et al. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 2009;4:1270-1273.